Clasado Bioscience’s Bimuno GOS now distributed in China by Shanghai Prochin
Clasado Biosciences has entered into an exclusive distribution agreement with Shanghai Prochin, a division of Alliance Nutrition Group, to make Clasado’s galactooligosaccharide ingredient Bimuno GOS available to formulators in China.
Photo © iStockphoto.com/skynesher
Clasado Biosciences (Berkshire, UK) has entered into an exclusive distribution agreement with Shanghai Prochin, a division of Alliance Nutrition Group, to make Clasado’s galactooligosaccharide ingredient Bimuno GOS available to formulators in China.
“We are delighted to partner with Prochin and enable our science-backed Bimuno GOS to be available in China as we expand our presence in the Asia-Pacific region. Over the last two years, our growing distributor network has seen Bimuno GOS become available in countries such as Thailand, Indonesia, Vietnam and Japan, so we are delighted to increase that footprint even further,” said David Mharakurwa, director of sales for APAC & MEA at Clasado, in a press release. “The commercial opportunity for Chinese formulators is clear. The Asian prebiotic market is expected to see a strong compound annual growth rate of over 15% according to market data firm Grand View Research, so it really is the ideal time to explore why Bimuno GOS, now backed by more than 120 publications, stands as the perfect choice.”
"We're committed to providing innovative ingredient solutions that meet the evolving needs of consumers, especially in terms of gut microbiome support. The inclusion of Bimuno GOS in our product portfolio underlines our dedication to putting science at the heart of formulation,” added Kévin Ransbotyn, general manager of B2B Ingredients at Alliance Nutrition Group. “Today’s health focused consumers are looking for products with strong scientific backing and evidence they can trust. Bimuno GOS shines as the most comprehensively studied commercially available prebiotic galactooliogosaccharide, with extensive research showing its advantages in gastrointestinal, immune and cognitive health, and beyond.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
